CN105477238A - Traditional Chinese medicine extract for treating cardiac conduction block and application thereof - Google Patents

Traditional Chinese medicine extract for treating cardiac conduction block and application thereof Download PDF

Info

Publication number
CN105477238A
CN105477238A CN201510908933.5A CN201510908933A CN105477238A CN 105477238 A CN105477238 A CN 105477238A CN 201510908933 A CN201510908933 A CN 201510908933A CN 105477238 A CN105477238 A CN 105477238A
Authority
CN
China
Prior art keywords
chinese medicine
medicine extract
traditional chinese
block
application
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN201510908933.5A
Other languages
Chinese (zh)
Inventor
孙科
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN201510908933.5A priority Critical patent/CN105477238A/en
Publication of CN105477238A publication Critical patent/CN105477238A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/64—Orobanchaceae (Broom-rape family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention relates to a traditional Chinese medicine extract for treating cardiac conduction block. The traditional Chinese medicine extract is characterized by being prepared from, by weight, 0.05-1% of ferulic acid, 0.02-0.05% of ergosta, 0.02-0.05% of glycoside cinnamaldehyde, 0.02-0.05% of eugenol, 1-2% of coenzyme Q1 and 0.05-1% of dracorhodin. The traditional Chinese medicine extract has the advantages of capability of removing stasis and easing pain, stopping bleeding and promoting granulation and functions of improving human immunity, enhancing resistance to oxidation, delaying senescence and improving human vitality.

Description

A kind of Chinese medicine extract and application for the treatment of heart block
Technical field
The present invention relates to technical field of Chinese medicines, be specifically related to a kind of Chinese medicine extract and application for the treatment of heart block.
Background technology
Heart block refers to that impulsion all can be slowed down or block in the conduction at any position of conducting system of heart.As occurred between sinuatrial node and atrium, claim sinoatrial block.Between atrium and ventricle, claim atrioventricular block.Be positioned at ventricle, be called intraventricular block.By the order of severity of conduction block, it is all effective to the atrioventricular block at any position that isoproterenol is commonly used in current treatment, but should be very prudent when being applied to acute myocardial infarction, because may serious ventricular arrhythmia be caused, therefore medication is first aid, temporary, and alleviation is main treatment, the untoward reaction that easy generation is serious, is only applicable to the case of emergency of acardia pace-making condition.Therefore, the slow person of, Ventricular Rate obvious for symptom, often give provisional or permanent cardiac pacing treatment, the activity for patient brings many troubles.
Summary of the invention
Treatment by Chinese herbs primary disease beneficial effect of the present invention is: removing blood stasis and relieving pain, hemostasia and promoting granulation, can improve body immunity, strengthen the functions such as antioxidation, slow down aging and enhancing human activity.
The object of the invention is, in order to solve above-mentioned technical deficiency, to provide good effect, short treating period, cure rate high, a kind of Chinese medicine extract and the application for the treatment of heart block had no side effect.
Treat Chinese medicine extract and the application of heart block for achieving the above object, it is characterized in that being made up of the percentage by weight of agents extract: ferulic acid 0.05-1%, containing Ergota steroid 0.02-0.05%, glycosides cinnamic aldehyde 0.02-0.05%, eugenol 0.02-0.05%, ubiquinone 101-2%, dracorhodin 0.05-1%.
Preparation technology: above-mentioned composition is mixed, dry, add cyclodextrin ratios and mix well by 1: 10, become relative density to be the clear paste of 1.25 ~ 1.30 (50 DEG C) after concentrated.
Chinese medicine extract ferulic acid (Ferulicacid) plant origin of the present invention: samphire Resina Ferulae FerulaassafoetidaL., Rhizoma Chuanxiong LigusticumchuanxiongHort. rhizome, lycopsid goodluck LycopodiumselagoL. herb, Equisetaceae plant Herba Equiseti Hiemalis EquisetumhiemaleL. herb, ranunculaceae plant Rhizoma Cimicifugae CimicifugafoetidaL. rhizome, Gramineae plant rice OryzasativaL. seed coat, liliaceous plant Bulbus Allii Cepae AlliumcepaL. root, bulb, leaf, crucifer Radix Raphani RaphanussativusL. root, Bignoniaceae plant Catalpa ovata Don. CatalpaovataG.Don bark, feverfew Anthemis nobilis AnthemisnobilisL. flower, Nyctaginaceae Plant Light leaf style BougainvilleaglabraChoisy root.Pharmacological action: ferulic acid (sodium ferulate) has antiplatelet aggregation, suppresses platelet 5-HT release, suppresses the generation of platelet thrombus element A2 (TXA2), strengthen prostaglandin activity, analgesia, the effects such as alleviating vascular spasm.Cinnamic aldehyde, eugenol derive from Cortex Cinnamomi extract composition: containing volatile oil, containing cinnamic aldehyde (cinnamaldehyde), eugenol (eugenol) etc. in oil, and containing tannin and phlegmatic temperament.Have warming and recuperating the kidney-YANG. warming middle-JIAO leads blood vessels by cold, a surname.Ergota steroid derives from the fleshy stem that this product is the dry zone scale leaf of orobanchaceae plant cistanche CistanchedeserticolaY.C.Ma.Nature and flavor with return through: sweet, salty, temperature.Return kidney, large intestine channel.Function with cure mainly: kidney-replenishing, benefiting essence-blood, loosening bowel to relieve constipation.Dracorhodin derives from Sanguis Draxonis extract.This product is that the resin that oozes out of babassu Sanguis Draxonis DaemonoropsdracoBl. fruit is through being processed into.Nature and flavor with return through: sweet, salty, flat.GUIXIN, Liver Channel.Function with cure mainly: removing blood stasis and relieving pain, hemostasia and promoting granulation.Lose for falling to flutter, ecchymoma due to internal injury; Continuous bleeding due to traumatic injury.Ubiquinone 10be that one is present in natural fat-soluble quinones, its structure and vitamin K, vitamin E are similar to plastoquinone.In human body cell, participate in energy manufacture and activation, be that prevention of arterial sclerosis forms the most effective antioxidation composition.Be a kind of fat-soluble antioxidant, the nutrition of energy human activin cell and cellular energy, has antioxidation anti-aging.Body immunity can be improved, strengthen the functions such as antioxidation, slow down aging and enhancing human activity, medically be widely used in cardiovascular system diseases.Above compatibility of drugs, brings out the best in each other.
The present invention verifies through clinical practice; Complete incidence graph 82.3%, total effective rate 97%.
Detailed description of the invention
Below in conjunction with enforcement case, the invention will be further described:
Embodiment 1: ferulic acid 0.05-1%, containing Ergota steroid 0.02-0.05%, glycosides cinnamic aldehyde 0.02-0.05%, eugenol 0.02-0.05%, ubiquinone 101-2%, dracorhodin 0.05-1%.Method for making, with above-mentioned, obtains clear paste 20 parts
Embodiment 2: ferulic acid 0.05%, containing Ergota steroid 0.02%, glycosides cinnamic aldehyde 0.02%, eugenol 0.02%, ubiquinone 101%, dracorhodin 0.05%.Method for making, with above-mentioned, obtains clear paste 20 parts.
Clinical efficacy is summed up
One, physical data: we are extensive in clinical practice for many years, selects patient 68 example altogether, wherein man 35 example, and female 33 example, average 56 years old, all patients all made a definite diagnosis through hospital above county level.
Two, diagnostic criteria: clinical manifestation atrioventricular block: once auriculoventricular block patient was usually asymptomatic.Second degree of auriculoventricular block can cause heartbeat to be left out, can had palpitation symptom, also can be asymptomatic.The symptom of the 3rd degree of auriculoventricular block depend on the speed of Ventricular Rate with pathological changes, symptom comprise tired, weak, dizzy, faint, angina pectoris, heart failure.As merged ventricular arrhythmia, patient can feel that cardiopalmus is uncomfortable.When first and second degree auriculoventricular block is in progress suddenly as Complete atrioventricular block, because Ventricular Rate causes cerebral ischemia excessively slowly, can there is temporary loss of consciousness in patient, even twitch, and is called Adams-Strokes syndrome, and severe patient can cause sudden death.Intraventricular block list props up, two retardances are usual without clinical symptoms.The clinical manifestation of completeness trifascicular block is identical with Complete atrioventricular block.Medical technologies check: auscultation and electrocardiogram true.
Efficacy determination:
Complete incidence graph: clinical symptoms disappears lasting more than 1 year completely.
Partial rcsponse: clinical symptom relief continues half a year more than.
Invalid: clinical symptoms is without alleviation.
Three, method of administration: each 10g, morning every day, 2 sub-services in evening 10th were 1 course for the treatment of.
Five, therapeutic effect: select patient 68 routine altogether, cure 56 examples, take a turn for the better 10 examples, and do not heal 2 examples, complete incidence graph 82.3%, partial rcsponse 14.7%, invalid 2.9%.Total effective rate 97%.
Six, model case
1. king XX, female, 55 years old, in June, 2012 went to a doctor.Main suit is tired before 3 hours, weak, dizzy, faint, the diagnosis second degree A-V block of local institute at county level.With isopropyl kidney for main treatment scheme, recurrent exerbation after taking a turn for the better, patient requests takes Chinese medicine 2 of the present invention course for the treatment of, remission.Drug withdrawal 2 days, continue to take for 1 course for the treatment of, symptom is all eliminated, and electrocardiographic examination is normal.Half a year, follow up a case by regular visits to for 1 year twice and do not recur.
2. Lee XX, man, 68 years old, in October, 2014 went to a doctor.Patient main suit is tired, weak, dizzy, faint and repeatedly show effect, chest pain one week, carrys out my institute's diagnosis second degree A-V block, and Western medicine of being in hospital is with isopropyl kidney for main treatment two weeks, and poor effect, patient requests takes Chinese medicine 3 of the present invention course for the treatment of, remission.Symptom complete incidence graph, electrocardiographic examination is normal.Half a year, follow up a case by regular visits to for 1 year twice and do not recur.
3. Hu XX, man, 72 years old, in February, 2015 went to a doctor.Patient main suit is tired, weak, dizzy, faint and repeatedly show effect, chest pain one week, carrys out my institute's clinical symptoms in conjunction with electrocardio, lab testing, diagnosis second degree A-V block.Western medicine poor effect, patient requests takes Chinese medicine 3 of the present invention course for the treatment of, symptom complete incidence graph, half a year, follows up a case by regular visits to for 1 year twice and does not recur.

Claims (2)

1. treat Chinese medicine extract and the application of heart block, it is characterized in that being made up of the percentage by weight of agents extract: ferulic acid 0.05-1%, containing Ergota steroid 0.02-0.05%, glycosides cinnamic aldehyde 0.02-0.05%, eugenol 0.02-0.05%, ubiquinone 101-2%, dracorhodin 0.05-1%.
2. treat the preparation technology of the Chinese medicine extract of heart block according to claim 1 one kind, it is characterized in that above-mentioned composition to mix, dry, add cyclodextrin ratios concentrated by 1: 10 after become relative density to be the clear paste of 1.25 ~ 1.30 (50 DEG C).
CN201510908933.5A 2015-12-06 2015-12-06 Traditional Chinese medicine extract for treating cardiac conduction block and application thereof Withdrawn CN105477238A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510908933.5A CN105477238A (en) 2015-12-06 2015-12-06 Traditional Chinese medicine extract for treating cardiac conduction block and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201510908933.5A CN105477238A (en) 2015-12-06 2015-12-06 Traditional Chinese medicine extract for treating cardiac conduction block and application thereof

Publications (1)

Publication Number Publication Date
CN105477238A true CN105477238A (en) 2016-04-13

Family

ID=55664752

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201510908933.5A Withdrawn CN105477238A (en) 2015-12-06 2015-12-06 Traditional Chinese medicine extract for treating cardiac conduction block and application thereof

Country Status (1)

Country Link
CN (1) CN105477238A (en)

Similar Documents

Publication Publication Date Title
CN103638462A (en) Chinese medicinal liquor for treating coronary heart disease and preparation method thereof
CA2537300C (en) Treatment of asprin resistance with radix salviae miltiorrhizae, its extract and composition
CN105477238A (en) Traditional Chinese medicine extract for treating cardiac conduction block and application thereof
EP2508084B1 (en) Biologically active food additive for treatment of myocardial ischemia
CN113171414A (en) A Chinese medicinal composition for treating coronary heart disease and angina pectoris
JP7435442B2 (en) Composition for improving vascular endothelial function or peripheral blood flow
CN106620253B (en) Traditional Chinese medicine composition for treating bradyarrhythmia
CN103550356B (en) Traditional Chinese medicinal composition for treating thrombus
CN113679781B (en) Traditional Chinese medicine composition for treating tachyarrhythmia and preparation method and application thereof
CN110882347A (en) A Chinese medicinal composition for treating cardiovascular diseases
KR102684027B1 (en) Composition for Preventing or Treating Hypertension
CN104013744B (en) Traditional Chinese medicine prescription for treating unstable angina pectoris of aged coronary heart disease
CN108379510A (en) A kind of Chinese medicine composition for treating angiocardiopathy
CN103316226B (en) Traditional Chinese medicine composition for treating coronary heart disease
CN103007200B (en) Medicament for treating coronary heart disease
CN103800723B (en) One is used for the treatment of ARR Chinese medicine composition and preparation method thereof
CN113144080B (en) Traditional Chinese medicine for treating coronary atherosclerotic plaques
CN104161840A (en) Application of Xinkeshu preparation in preparation of medicine for treating coronary heart disease combined arrhythmia with psychological problems of anxiety and depression and preparation method of Xinkeshu preparation
CN104606549A (en) Traditional Chinese medicine for treating viral myocarditis
CN207125908U (en) For coronary disease and angina pectoris paster
CN104825682A (en) Traditional Chinese medicine for treatment of coronary heart disease angina pectoris
CN100411641C (en) Use of dripping pill in preparing medicine for treating anti-aspirin
CN113694130A (en) A Chinese medicinal composition for treating diabetic cardiac lesion and preparation method thereof
CN105434531A (en) Flavone composition for treating heart block and preparation
CN103239620B (en) Traditional Chinese medicine for treating qi-deficiency heart diseases

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication

Application publication date: 20160413

WW01 Invention patent application withdrawn after publication